OFF-LABEL USE OF LINCOMYCIN HYDROCHLORIDE IN 2 HORSES - INADEQUATE SYMPTOMATIC TREATMENT RESULTING IN DYSBACTERIOSIS AND FATAL COMPLICATIONS

被引：0
|
作者：
VANMIERT, ASJPAM
机构：
来源：
TIJDSCHRIFT VOOR DIERGENEESKUNDE | 1995年 / 120卷 / 12期
关键词：
D O I：
暂无
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
A lawyer enquired about the possible harmful effects of 'off-label use' of lincomycin in two trotting horses. From information in the relevant dossier it could be concluded that there was no direct indication to use antibiotics. In addition, mistakes were made in the medicinal treatment of horses, namely, the off-label use of lincomycin without prior consultation with the manufacturer, fluid and electrolyte replacement therapy not continued for long enough, and incorrect use of antipyretic analgesics. The intravenous administration of gentamicin to dehydrated patients is permissible only in combination with adequate administration of fluids and electrolytes.
引用
收藏
页码：361 / 363
页数：3
相关论文
共 13 条
  • [1] Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
    Morena, Valentina
    Milazzo, Laura
    Oreni, Letizia
    Bestetti, Giovanna
    Fossali, Tommaso
    Bassoli, Cinzia
    Torre, Alessandro
    Cossu, Maria Vittoria
    Minari, Caterina
    Ballone, Elisabetta
    Perotti, Andrea
    Mileto, Davide
    Niero, Fosca
    Merli, Stefania
    Foschi, Antonella
    Vimercati, Stefania
    Rizzardini, Giuliano
    Sollima, Salvatore
    Bradanini, Lucia
    Galimberti, Laura
    Colombo, Riccardo
    Micheli, Valeria
    Negri, Cristina
    Ridolfo, Anna Lisa
    Meroni, Luca
    Galli, Massimo
    Antinori, Spinello
    Corbellino, Mario
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 76 : 36 - 42
  • [2] Multiple drugsCOVID-19, and treatment failure following off-label use: 2 case reports
    Reactions Weekly, 2021, 1872 (1) : 329 - 329
  • [3] Off-label Use of Citrate in the Treatment of Combined D- and L-2-Hydroxyglutaric Aciduria
    Zuccarelli, B. D.
    Smith, L. D.
    Saunders, C. J.
    Atherton, A. M.
    Miller, N.
    Kingsmore, S. F.
    Farrow, E. G.
    Willig, L. K.
    LePichon, J. B.
    ANNALS OF NEUROLOGY, 2014, 76 : S215 - S215
  • [4] Evaluation of complications associated with off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in pediatric orthopaedics
    Norbert Stiel
    Tim N. Hissnauer
    Martin Rupprecht
    Kornelia Babin
    Carsten W. Schlickewei
    Johannes M. Rueger
    Ralf Stuecker
    Alexander S. Spiro
    Journal of Materials Science: Materials in Medicine, 2016, 27
  • [5] Evaluation of complications associated with off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in pediatric orthopaedics
    Stiel, Norbert
    Hissnauer, Tim N.
    Rupprecht, Martin
    Babin, Kornelia
    Schlickewei, Carsten W.
    Rueger, Johannes M.
    Stuecker, Ralf
    Spiro, Alexander S.
    JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 2016, 27 (12)
  • [6] Heavily Calcified Symptomatic Carotid Stenosis Treated With Off-Label Use of Lithotripsy Balloon Plus Stenting: 2-Dimensional Operative Video
    De Toledo, Otavio F.
    Gutierrez-Aguirre, Salvador F.
    Benalia, Victor H. C.
    Lara-Velazquez, Montserrat
    Aghaebrahim, Amin
    Sauvageau, Eric
    Hanel, Ricardo A.
    OPERATIVE NEUROSURGERY, 2024, 27 (01) : 126 - 126
  • [7] Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
    Chen, Kuan-Yuan
    Lee, Kang-Yun
    Qin, Albert
    Luo, Ching-Shan
    Yeh, Yun-Kai
    Zheng, Jing-Quan
    Chen, Ching-Mei
    Tsai, Chan-Yen
    Lin, Sheena
    Liao, Jason
    Huang, Yi-Wen
    Feng, Po-Hao
    ADVANCES IN THERAPY, 2022, 39 (02) : 910 - 922
  • [8] Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
    Kuan-Yuan Chen
    Kang-Yun Lee
    Albert Qin
    Ching-Shan Luo
    Yun-Kai Yeh
    Jing-Quan Zheng
    Ching-Mei Chen
    Chan-Yen Tsai
    Sheena Lin
    Jason Liao
    Yi-Wen Huang
    Po-Hao Feng
    Advances in Therapy, 2022, 39 : 910 - 922
  • [9] Recombinant human bone morphogenetic protein-2 use in the off-label treatment of nonunions and acute fractures: A retrospective review
    Starman, James S.
    Bosse, Michael J.
    Cates, Casey A.
    Norton, H. James
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2012, 72 (03): : 676 - 681
  • [10] OFF-LABEL USE OF BIOLOGIC AGENTS IN THE TREATMENT OF DERMATOSIS, PART 2: ETANERCEPT, EFALIZUMAB, ALEFACEPT, RITUXIMAB, DACLIZUMAB, BASILIXIMAB, OMALIZUMAB, AND CETUXIMAB
    Guhl, G.
    Diaz-Ley, B.
    Fernandez-Herrera, J.
    ACTAS DERMO-SIFILIOGRAFICAS, 2008, 99 (01): : 5 - 33
12